|Day Low/High||33.92 / 35.18|
|52 Wk Low/High||22.51 / 61.69|
CMPS may be a company representing the true cannabis 2.0. The irony in that is it isn't a cannabis company but rather a play on psilocybin.
Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.
Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.
Fresh off IPO, company sees mushrooming opportunity in psilocybin.